
Changes in Dyspepsia-specific Quality of Life Scores From Baseline at Week 4
NDI-K scores | Mosapride citrate SR group (n = 51) | Mosapride citrate CR group (n = 49) | Intergroup P-value |
---|---|---|---|
Total | |||
Baseline | 276.34 ± 76.11 | 288.57 ± 70.79 | 0.465 |
Week 4 | 340.16 ± 80.48 | 355.69 ± 85.46 | |
Change |
63.82 ± 82.91 | 67.12 ± 81.11 | > 0.999 |
In group |
< 0.001 |
< 0.001 |
|
Tension/sleep | |||
Baseline | 58.14 ± 19.00 | 60.22 ± 17.16 | 0.567 |
Week 4 | 73.38 ± 17.55 | 75.45 ± 19.62 | |
Change |
15.23 ± 20.27 | 15.23 ± 18.59 | 0.890 |
In group |
< 0.001 |
< 0.001 |
|
Interference with daily activities | |||
Baseline | 57.23 ± 16.14 | 58.43 ± 17.56 | 0.721 |
Week 4 | 65.61 ± 18.38 | 69.23 ± 18.86 | |
Change |
8.38 ± 18.94 | 10.79 ± 19.38 | 0.497 |
In group |
< 0.001 |
< 0.001 |
|
Eating/drinking | |||
Baseline | 56.78 ± 19.45 | 59.01 ± 16.74 | 0.541 |
Week 4 | 71.46 ± 19.11 | 74.04 ± 20.47 | |
Change |
14.68 ± 18.98 | 15.02 ± 20.22 | 0.909 |
In group P-value | < 0.001 |
< 0.001 |
|
Knowledge/control | |||
Baseline | 46.51 ± 17.72 | 51.15 ± 15.68 | 0.145 |
Week 4 | 61.34 ± 18.00 | 64.92 ± 18.00 | |
Change |
14.83 ± 20.28 | 13.78 ± 17.62 | 0.783 |
In group |
< 0.001 |
< 0.001 |
|
Work/study | |||
Baseline | 57.68 ± 17.26 | 59.75 ± 17.49 | 0.553 |
Week 4 | 68.38 ± 20.26 | 72.05 ± 19.71 | |
Change |
10.70 ± 20.58 | 12.30 ± 20.11 | 0.984 |
In group |
< 0.001 |
< 0.001 |
NDI-K, Nepean Dyspepsia Index-Korean version.
aChanges in score related to symptoms (week 4-baseline).
bTwo-sample
cWilcoxon signed rank test.
dPaired
eWilcoxon rank sum test.